Tuesday, November 6, 2012

Vivus Inc, Express Scripts Holding Slump On Earnings Miss – VVUS, ESRX

Shares of VIVUS, Inc.(NASDAQ:VVUS) fell by $3.16 or 21.14% to $11.79 in the morning session as the company posted a wider than estimated loss in the Q3.

Vivus posted a net loss of $40.40 million or $0.40 cents per share in comparison to $8.63 million 0r $0.10 cents per share for the last year.

Is It the Right Time to Buy VVUS after Today’s Slump? We Have Special Report Here

The biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, primarily attributed increased selling, general and administrative expenses related to pre-commercialization and commercialization activities for Qsymia to be the reasons for increase in net loss.

The start-up costs associated with the post-approval studies for Qsymia and STENDRA led to increase in research and development expenses.

Prescriptions shipped from certified pharmacies to patients helped the company to recognize net product revenue of $41 thousand for the third quarter.

Stocks of Express Scripts Holding Company(NASDAQ:ESRX) fell by $8.70 or 13.84% to $54.18 in the morning session as the company deemed the analyst forecast for year 2013 as "overly aggressive," which casted doubts as to how well the company is integrating its $29 billion purchase of Medco Health Solutions Inc.

How Should Investors Trade ESRX After Today’s Slump? Get Free Trend Analysis Here

Excluding special items the third quarter earnings were $1.02, arise by 29% in comparison to last year, which beats analyst expectation of 99 cents per share according to Thomson Reuters I/B/E/S.

Further net income rose by 21% to $391.4 million as compared to last year. Revenue increased by 133% to $27 billion. Claims rose 116 percent to 398.6 million.

Raising the lower end of its forecast range for 2012 earnings by 5 cents Express Scripts projects full-year profit this year of $3.65 to $3.75 a share.

Analyst projects $4.49 a share in 2013, according to Thomson Reuters I/B/E/S. But the company said the analyst forecast to be too aggressive.

No comments:

Post a Comment

Privacy Policy | Legal Disclaimer